Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Geographic Atrophy Secondary to Age-related Macular Degeneration”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT03178149
What this trial is testing

The Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

Who this might be right for
Age-Related Macular Degeneration
Astellas Institute for Regenerative Medicine 42
Testing effectiveness (Phase 2)Ended earlyNCT04566445
What this trial is testing

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Who this might be right for
Dry Age-related Macular Degeneration
Gyroscope Therapeutics Limited 255
Large-scale testing (Phase 3)Study completedNCT04770545
What this trial is testing

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

Who this might be right for
Geographic Atrophy Secondary to Age-related Macular Degeneration
Apellis Pharmaceuticals, Inc. 792
Early research (Phase 1)Study completedNCT04246866
What this trial is testing

First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration

Who this might be right for
Dry Age-related Macular DegenerationGeographic AtrophyMacular Degeneration+2 more
Gemini Therapeutics, Inc. 12
Large-scale testing (Phase 3)Study completedNCT03525600
What this trial is testing

Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

Who this might be right for
Geographic Atrophy
Apellis Pharmaceuticals, Inc. 621
Testing effectiveness (Phase 2)Looking for participantsNCT06765980
What this trial is testing

Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

Who this might be right for
Geographic Atrophy Secondary to Age-related Macular Degeneration
Kriya Therapeutics, Inc. 62
Testing effectiveness (Phase 2)Study completedNCT05811351
What this trial is testing

Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Who this might be right for
Geographic Atrophy
Janssen Research & Development, LLC 305
Testing effectiveness (Phase 2)Ended earlyNCT04607148
What this trial is testing

A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Who this might be right for
Macular Degeneration, Age-RelatedGeographic Atrophy
Genentech, Inc. 144
Not applicableLooking for participantsNCT07531927
What this trial is testing

Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy

Who this might be right for
Geographic Atrophy Secondary to Age-related Macular Degeneration
Okuvision GmbH 70
Large-scale testing (Phase 3)Study completedNCT04435366
What this trial is testing

Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Who this might be right for
Geographic AtrophyMacular Degeneration
IVERIC bio, Inc. 448
Testing effectiveness (Phase 2)Looking for participantsNCT07215390
What this trial is testing

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

Who this might be right for
Geographic Atrophy Secondary to Age-related Macular Degeneration
Apellis Pharmaceuticals, Inc. 240
Not applicableStudy completedNCT06499571
What this trial is testing

Geographic Atrophy Long-Terms Outcomes Study

Who this might be right for
Geographic Atrophy
Apellis Pharmaceuticals, Inc. 255
Post-approval studies (Phase 4)Study completedNCT05269966
What this trial is testing

Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular Degeneration (nAMD)
Novartis Pharmaceuticals 105
Not applicableActive Not RecruitingNCT06779773
What this trial is testing

Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Who this might be right for
Geographic AtrophyMacular Degeneration
Astellas Pharma Global Development, Inc. 489
Testing effectiveness (Phase 2)Looking for participantsNCT06990269
What this trial is testing

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Who this might be right for
Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc. 240
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05481827
What this trial is testing

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

Who this might be right for
Age Related Macular Degeneration (AMD)
Gyroscope Therapeutics Limited 225
Not applicableStudy completedNCT07424235
What this trial is testing

Evaluating the Relationship Between Function and Structure Using Data From a GA Natural History Cohort

Who this might be right for
Age Related Macular Degeneration (AMD)Age Related Macular DegenerationAMD+3 more
IRCCS Ospedale San Raffaele 60
Testing effectiveness (Phase 2)Ended earlyNCT03972709
What this trial is testing

A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Who this might be right for
Macular Degeneration, Age-RelatedGeographic Atrophy
Genentech, Inc. 372
Large-scale testing (Phase 3)Study completedNCT04005352
What this trial is testing

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

Who this might be right for
Age-related Macular Degeneration
Novartis Pharmaceuticals 734
Post-approval studies (Phase 4)Study completedNCT04679935
What this trial is testing

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

Who this might be right for
Age-related Macular Degeneration
Novartis Pharmaceuticals 52
Next Page